Alzheimer’s disease (AD) is a neurodegenerative condition that displays a high prevalence in Lebanon causing a local burden in healthcare and socio-economic sectors. Unfortunately, the lack of prevalence studies and clinical trials in Lebanon minimizes the improvement of AD patient health status. In this review, we include over 155 articles to cover the different aspects of AD ranging from mechanisms to possible treatment and management tools. We highlight some important modifiable and non-modifiable risk factors of the disease including genetics, age, cardiovascular diseases, smoking, etc. Finally, we propose a hypothetical genetic synergy model between APOE4 and TREM2 genes which constitutes a potential early diagnostic tool that helps in reducing the risk of AD based on preventative measures decades before cognitive decline. The studies on AD in Lebanon and the Middle East are scarce. This review points out the importance of genetic mapping in the understanding of disease pathology which is crucial for the emergence of novel diagnostic tools. Hence, we establish a rigid basis for further research to identify the most influential genetic and environmental risk factors for the purpose of using more specific diagnostic tools and possibly adopting a local management protocol.
DeTureMA, DicksonDW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener14, 32.
4.
ReitzC, RogaevaE, BeechamGW (2020) Late-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference? Neurol Genet6, e512.
5.
MendezMF (2019) Early-onset Alzheimer disease and its variants. Contin Lifelong Learn Neurol25, 34–51.
6.
BarnesJ, DickersonBC, FrostC, JiskootLC, WolkD, Van Der FlierWM (2015) Alzheimer’s disease first symptoms are age dependent: Evidence from the NACC dataset. Alzheimers Dement11, 1349–1357.
7.
BringasS, SalomónS, DuqueR, LageC, MontañaJL (2020) Alzheimer’s disease stage identification using deep learning models. J Biomed Inform109, 103514.
8.
ParnettiL, ChipiE, SalvadoriN, D’AndreaK, EusebiP (2019) Prevalence and risk of progression of preclinical Alzheimer’s disease stages: A systematic review and meta-analysis. Alzheimers Res Ther11, 7.
9.
Alzheimer’s Association (2019) Alzheimer’s disease facts and figures. Alzheimers Dement15, 321–387.
NicholsE, SteinmetzJD, VollsetSE, FukutakiK, ChalekJ, Abd-AllahF, AbdoliA, AbualhasanA, Abu-GharbiehE, AkramTT, et al. (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health7, e105–e125.
12.
(2023) 2023 Alzheimer’s disease facts and figures. Alzheimers Dement19, 1598–1695.
13.
IwatsuboT, NiimiY, AkiyamaH (2021) Alzheimer’s disease research in Japan: A short history, current status and future perspectives toward prevention. J Prev Alzheimers Dis8, 462–464.
GustavssonA, NortonN, FastT, FrölichL, GeorgesJ, HolzapfelD, KirabaliT, Krolak-SalmonP, RossiniPM, FerrettiMT, LanmanL, ChadhaAS, Van Der FlierWM (2023) Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement19, 658–670.
16.
LiX, FengX, SunX, HouN, HanF, LiuY (2022) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2019. Front Aging Neurosci14, 937486.
17.
AbyadA (2022) Geriatrics and care of the elderly in the Middle East and Africa: Challenges and opportunities! . Ibnosina J Med Biomed Sci14, 003–005.
18.
EL TallawyHNA, FarghalyWMA, El HamedMA, BadryR, UsamaK, ShehataGA, TohamyAM, AbdulghaniKO, GhanemMK, SayedMA, YousefAH, HashemHS, RagehTA (2019) Prevalence of Alzheimer dementia in Upper Egypt (desert areas). Egypt J Neurol Psychiatry Neurosurg55, 29.
19.
NavipourE, NeamatshahM, BarabadiZ, NeamatshahM, KeykhosraviA (2019) Epidemiology and risk factors of Alzheimer’s disease in Iran: A systematic review. Iran J Public Health48, 2133–2139.
20.
HajemS, SaidiO, Ben MansourN, MejdoubY, HsairiM (2014) Épidémiologie des démences en Tunisie. NPG Neurol Psychiatr Gériatrie14, 326–333.
21.
KhaledM (2010) Spot light on Alzheimer’s disease in the North Lebanon. Middle East J Psychiatry Alzheimers1, 21–37.
22.
PhungKTT, ChaayaM, PrinceM, AtwehS, El AsmarK, KaramG, KhouryRM, GhandourL, GhusnH, NielsenTR, WaldemarG (2017) Dementia prevalence, care arrangement, and access to care in Lebanon: A pilot study. Alzheimers Dement13, 1317–1326.
23.
GourasGK, OlssonTT, HanssonO (2015)
β-amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics12, 3–11.
24.
HuangY, LiuR (2020) The toxicity and polymorphism of β-amyloid oligomers. Int J Mol Sci21, 4477.
25.
YanY, XuT-H, MelcherK, XuHE (2017) Defining the minimum substrate and charge recognition model of gamma-secretase. Acta Pharmacol Sin38, 1412–1424.
26.
Tarasoff-ConwayJM, CarareRO, OsorioRS, GlodzikL, ButlerT, FieremansE, AxelL, RusinekH, NicholsonC, ZlokovicBV, FrangioneB, BlennowK, MénardJ, ZetterbergH, WisniewskiT, De LeonMJ (2015) Clearance systems in the brain—implications for Alzheimer disease. Nat Rev Neurol11, 457–470.
27.
DanyszW, ParsonsCG (2012) Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine-searching for the connections. Br J Pharmacol167, 324–352.
28.
BrierMR, GordonB, FriedrichsenK, McCarthyJ, SternA, ChristensenJ, OwenC, AldeaP, SuY, HassenstabJ, CairnsNJ, HoltzmanDM, FaganAM, MorrisJC, BenzingerTLS, AncesBM (2016) Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Transl Med8, 338ra66.
29.
ChastagnerP, LoriaF, VargasJY, ToisJ, I DiamondM, OkafoG, BrouC, ZurzoloC (2020) Fate and propagation of endogenously formed Tau aggregates in neuronal cells. EMBO Mol Med12, e12025.
30.
DrummondE, PiresG, MacMurrayC, AskenaziM, NayakS, BourdonM, SafarJ, UeberheideB, WisniewskiT (2020) Phosphorylated tau interactome in the human Alzheimer’s disease brain. Brain143, 2803–2817.
31.
NeddensJ, TemmelM, FlunkertS, KerschbaumerB, HoellerC, LoefflerT, NiederkoflerV, DaumG, AttemsJ, Hutter-PaierB (2018) Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun6, 52.
AshfordJW (2019) Treatment of Alzheimer’s disease: Trazodone, sleep, serotonin, norepinephrine, and future directions. J Alzheimers Dis67, 923–930.
34.
LiuN, SunS, WangP, SunY, HuQ, WangX (2021) The mechanism of secretion and metabolism of gut-derived 5-hydroxytryptamine. Int J Mol Sci22, 7931.
35.
HuZ, YingX, HuangL, ZhaoY, ZhouD, LiuJ, ZhongJ, HuangT, ZhangW, ChengF, DuanS (2020) Association of human serotonin receptor 4 promoter methylation with autism spectrum disorder. Medicine (Baltimore)99, e18838.
36.
ZhuangZ, YangR, WangW, QiL, HuangT (2020) Associations between gut microbiota and Alzheimer’s disease, major depressive disorder, and schizophrenia. J Neuroinflammation17, 288.
37.
GründerG, CummingP (2021) Serotonin and amyloid deposition: A link between depression and Alzheimer’s disease?: An Editorial Highlight on “Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer’s disease” on page 658. J Neurochem156, 560–562.
38.
BhattaraiP, CosacakMI, MashkaryanV, DemirS, PopovaSD, GovindarajanN, BrandtK, ZhangY, ChangW, AmpatzisK, KizilC (2020) Neuron-glia interaction through Serotonin-BDNF-NGFR axis enables regenerative neurogenesis in Alzheimer’s model of adult zebrafish brain. PLoS Biol18, e3000585.
39.
MarucciG, BuccioniM, BenDD, LambertucciC, VolpiniR, AmentaF (2021) Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology190, 108352.
40.
JaneczekM, GefenT, SamimiM, KimG, WeintraubS, BigioE, RogalskiE, MesulamM-M, GeulaC (2018) Variations in acetylcholinesterase activity within human cortical pyramidal neurons across age and cognitive trajectories. Cereb Cortex28, 1329–1337.
BanksSJ, AndrewsMJ, DigmaL, MadsenJ, ReasET, CaldwellJZK, McEvoyLK, FanCC, DaleAM, BrewerJB (2021) Sex differences in Alzheimer’s disease: Do differences in tau explain the verbal memory gap? Neurobiol Aging107, 70–77.
43.
ShokouhiS, TaylorWD, AlbertK, KangH, NewhousePA, The Alzheimer’s Disease Neuroimaging Initiative (2020) In vivo network models identify sex differences in the spread of tau pathology across the brain. Alzheimers Dement (Amst)12, e12016.
44.
SilvaMVF, LouresCDMG, AlvesLCV, De SouzaLC, BorgesKBG, CarvalhoMDG (2019) Alzheimer’s disease: Risk factors and potentially protective measures. J Biomed Sci26, 33.
45.
MooreMR, ChungJ, RosenthalerM, UretskyM, AbdolmohammadiB, RaghavanNS, FarrellJ, BennettDA, CranePK, KambohMI (2020) Genome-wide interaction study of smoking in Alzheimer’s disease: Genetics/genetic factors of Alzheimer’s disease. Alzheimers Dement16, e046149.
46.
PervinZ, StephenJM (2021) Effect of alcohol on the central nervous system to develop neurological disorder: Pathophysiological and lifestyle modulation can be potential therapeutic options for alcohol-induced neurotoxication. AIMS Neurosci8, 390–413.
47.
Solé-PadullésC, Bartrés-FazD, JunquéC, VendrellP, RamiL, ClementeIC, BoschB, VillarA, BargallóN, JuradoMA, BarriosM, MolinuevoJL (2009) Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging30, 1114–1124.
48.
De BruijnRF, IkramMA (2014) Cardiovascular risk factors and future risk of Alzheimer’s disease. BMC Med12, 130.
49.
KaoY-C, HoP-C, TuY-K, JouI-M, TsaiK-J (2020) Lipids and Alzheimer’s disease. Int J Mol Sci21, 1505.
50.
GhribiO (2008) Potential mechanisms linking cholesterol to Alzheimer’s disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis15, 673–684.
51.
OlmastroniE, MolariG, De BeniN, ColpaniO, GalimbertiF, GazzottiM, ZambonA, CatapanoAL, CasulaM (2022) Statin use and risk of dementia or Alzheimer’s disease: A systematic review and meta-analysis of observational studies. Eur J Prev Cardiol29, 804–814.
52.
LloretA, MonllorP, EsteveD, Cervera-FerriA, LloretM-A (2019) Obesity as a risk factor for Alzheimer’s disease: Implication of leptin and glutamate. Front Neurosci13, 508.
53.
TumminiaA, VinciguerraF, ParisiM, FrittittaL (2018) Type 2 diabetes mellitus and Alzheimer’s disease: Role of insulin signalling and therapeutic implications. Int J Mol Sci19, 3306.
54.
Al QahtanyFHM, Al ShaliHA, BayaminAA (2018) Atherosclerosis: Pathophysiology and management. Egypt J Hosp Med70, 82–87.
55.
ShabirO, BerwickJ, FrancisSE (2018) Neurovascular dysfunction in vascular dementia, Alzheimer’s and atherosclerosis. BMC Neurosci19, 62.
56.
RaoRV, SubramaniamKG, GregoryJ, BredesenAL, CowardC, OkadaS, KellyL, BredesenDE (2023) Rationale for a multi-factorial approach for the reversal of cognitive decline in Alzheimer’s disease and MCI: A review. Int J Mol Sci24, 1659.
57.
De La RosaA, Olaso-GonzalezG, Arc-ChagnaudC, MillanF, Salvador-PascualA, García-LucergaC, Blasco-LafargaC, Garcia-DominguezE, CarreteroA, CorreasAG, ViñaJ, Gomez-CabreraMC (2020) Physical exercise in the prevention and treatment of Alzheimer’s disease. J Sport Health Sci9, 394–404.
BaroniL, BonettoC, RizzoG, BertolaC, CaberlottoL, BazzerlaG (2019) Association between cognitive impairment and vitamin B12, folate, and homocysteine status in elderly adults: A retrospective study. J Alzheimers Dis70, 443–453.
60.
KwokT, WuY, LeeJ, LeeR, YungCY, ChoiG, LeeV, HarrisonJ, LamL, MokV (2020) A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. Clin Nutr39, 2399–2405.
61.
KimS, ChoiBY, NamJH, KimMK, OhDH, YangYJ (2019) Cognitive impairment is associated with elevated serum homocysteine levels among older adults. Eur J Nutr58, 399–408.
62.
MaF, WuT, ZhaoJ, JiL, SongA, ZhangM, HuangG (2017) Plasma homocysteine and serum folate and vitamin B12 levels in mild cognitive impairment and Alzheimer’s disease: A case-control study. Nutrients9, 725.
63.
SunJ, WenS, ZhouJ, DingS (2017) Association between malnutrition and hyperhomocysteine in Alzheimer’s disease patients and diet intervention of betaine. J Clin Lab Anal31, e22090.
64.
MarkunS, GravestockI, JägerL, RosemannT, PichierriG, BurgstallerJM (2021) Effects of vitamin B12 supplementation on cognitive function, depressive symptoms, and fatigue: A systematic review, meta-analysis, and meta-regression. Nutrients13, 923.
65.
KhosraviM, SotoudehG, AminiM, RaisiF, MansooriA, HosseinzadehM (2020) The relationship between dietary patterns and depression mediated by serum levels of Folate and vitamin B12. BMC Psychiatry20, 63.
OhES, RosenbergPB, RattingerGB, StuartEA, LyketsosCG, LeoutsakosJS (2021) Psychotropic medication and cognitive, functional, and neuropsychiatric outcomes in Alzheimer’s disease (AD). J Am Geriatr Soc69, 955–963.
68.
BanerjeeS, HighJ, StirlingS, ShepstoneL, SwartAM, TellingT, HendersonC, BallardC, BenthamP, BurnsA, FarinaN, FoxC, FrancisP, HowardR, KnappM, LeroiI, LivingstonG, NilforooshanR, NurockS, O’BrienJ, PriceA, ThomasAJ, TabetN (2021) Study of mirtazapine for agitated behaviours in dementia (SYMBAD): A randomised, double-blind, placebo-controlled trial. Lancet398, 1487–1497.
69.
MaierF, SpottkeA, BachJ-P, BartelsC, BuergerK, DodelR, FellgiebelA, FliessbachK, FrölichL, HausnerL, HellmichM, KlöppelS, KlostermannA, KornhuberJ, LaskeC, PetersO, PrillerJ, Richter-SchmidingerT, SchneiderA, Shah-HosseiniK, TeipelS, Von ArnimCAF, WiltfangJ, JessenF (2020) Bupropion for the treatment of apathy in Alzheimer disease: A randomized clinical trial. JAMA Netw Open3, e206027.
70.
LiZ, MoniruzzamanM, DastgheybRM, YooS, WangM, HaoH, LiuJ, CasacciaP, Nogueras-OrtizC, KapogiannisD, SlusherBS, HaugheyNJ (2020) Astrocytes deliver CK1 to neurons via extracellular vesicles in response to inflammation promoting the translation and amyloidogenic processing of APP. J Extracell Vesicles10, e12035.
71.
HuangC-W, HsuS-W, TsaiS-J, ChenN-C, LiuM-E, LeeC-C, HuangS-H, ChangW-N, ChangY-T, TsaiW-C, ChangC-C (2017) Genetic effect of interleukin-1 beta (C-511T) polymorphism on the structural covariance network and white matter integrity in Alzheimer’s disease. J Neuroinflammation14, 12.
72.
YinY, LiuY, PanX, ChenR, LiP, WuH-J, ZhaoZ-Q, LiY-P, HuangL-Q, ZhuangJ-H, ZhaoZ-X (2016) Interleukin-1β promoter polymorphism enhances the risk of sleep disturbance in Alzheimer’s disease. PLoS One11, e0149945.
73.
HendersonST, PoirierJ (2011) Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer’s disease; a randomized, double-blind, placebo-controlled study. BMC Med Genet12, 137.
74.
GhoshS, WuMD, ShaftelSS, KyrkanidesS, LaFerlaFM, OlschowkaJA, O’BanionMK (2013) Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J Neurosci33, 5053–5064.
75.
Al-BaradieRS, PuS, LiuD, ZeinolabedinyY, FerrisG, SanfeliC, CorpasR, Garcia-LaraE, AlsagabySA, AlshehriBM, Abdel-hadiAM, AhmadF, MoatariP, HeidariN, SlevinM (2021) Monomeric C-reactive protein localized in the cerebral tissue of damaged vascular brain regions is associated with neuro-inflammation and neurodegeneration-an immunohistochemical study. Front Immunol12, 644213.
76.
SlevinM, MatouS, ZeinolabedinyY, CorpasR, WestonR, LiuD, BorasE, Di NapoliM, PetcuE, SarrocaS, Popa-WagnerA, LoveS, FontMA, PotempaLA, Al-BaradieR, SanfeliuC, RevillaS, BadimonL, KrupinskiJ (2015) Monomeric C-reactive protein–a key molecule driving development of Alzheimer’s disease associated with brain ischaemia? Sci Rep5, 13281.
77.
ContrerasJA, AslanyanV, SweeneyMD, SandersLMJ, SagareAP, ZlokovicBV, TogaAW, HanSD, MorrisJC, FaganA, MassoumzadehP, BenzingerTL, PaJ (2020) Functional connectivity among brain regions affected in Alzheimer’s disease is associated with CSF TNF-α in APOE4 carriers. Neurobiol Aging86, 112–122.
78.
WoodLB, WinslowAR, ProctorEA, McGuoneD, MordesDA, FroschMP, HymanBT, LauffenburgerDA, HaigisKM (2015) Identification of neurotoxic cytokines by profiling Alzheimer’s disease tissues and neuron culture viability screening. Sci Rep5, 16622.
79.
GabbitaSP, SrivastavaMK, EslamiP, JohnsonMF, KobritzNK, TweedieD, GreigNH, ZemlanFP, SharmaSP, Harris-WhiteME (2012) Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. J Neuroinflammation9, 99.
80.
TanziRE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med2, a006296.
81.
Freudenberg-HuaY, LiW, DaviesP (2018) The role of genetics in advancing precision medicine for Alzheimer’s disease—a narrative review. Front Med5, 108.
82.
BellenguezC, Grenier-BoleyB, LambertJ-C (2020) Genetics of Alzheimer’s disease: Where we are, and where we are going. Curr Opin Neurobiol61, 40–48.
83.
MisraA, ChakrabartiS, GambhirI (2018) New genetic players in late-onset Alzheimer’s disease: Findings of genome-wide association studies. Indian J Med Res148, 135.
YonemuraY, FutaiE, YagishitaS, SuoS, TomitaT, IwatsuboT, IshiuraS (2011) Comparison of presenilin 1 and presenilin 2 γ-secretase activities using a yeast reconstitution system. J Biol Chem286, 44569–44575.
86.
CrutsM, Van DuijnCM, BackhovensH, Van Den BroeckM, WehnertA, SerneelsS, SherringtonR, HuttonM, HardyJ, St George-HyslopPH, HofmanA, Van BroeckhovenC (1998) Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet7, 43–51.
87.
ZhangX, LiY, XuH, ZhangYW (2014) The γ-secretase complex: From structure to function. Front Cell Neurosci8, 427.
DeatonCA, JohnsonGVW (2020) Presenilin 1 regulates membrane homeostatic pathways that are dysregulated in Alzheimer’s disease. J Alzheimers Dis77, 961–977.
90.
AnSS, CaiY, KimS (2015) Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders. Clin Interv Aging10, 1163–1172.
GeM, ZhangJ, ChenS, HuangY, ChenW, HeL, ZhangY (2022) Role of calcium homeostasis in Alzheimer’s disease. Neuropsychiatr Dis Treat18, 487–498.
93.
ZhangH, SunS, HerremanA, De StrooperB, BezprozvannyI (2010) Role of presenilins in neuronal calcium homeostasis. J Neurosci30, 8566–8580.
94.
SmitsLL, PijnenburgYA, van der VliesAE, KoedamEL, BouwmanFH, ReulingIE, ScheltensP, van der FlierWM (2015) Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains. Eur Neuropsychopharmacol25, 1010–1017.
95.
ChenH-H, PettyLE, ShaJ, ZhaoY, KuzmaA, ValladaresO,
Alzheimer’s Disease Genetics Consortium,
International Genomics of Alzheimer’s Project,
BushW, NajAC, GamazonER, BelowJE (2021) Genetically regulated expression in late-onset Alzheimer’s disease implicates risk genes within known and novel loci. Transl Psychiatry11, 618.
96.
RosenthalSL, KambohMI (2014) Late-onset Alzheimer’s disease genes and the potentially implicated pathways. Curr Genet Med Rep2, 85–101.
97.
KönigT, StögmannE (2021) Genetics of Alzheimer’s disease. Wien Med Wochenschr171, 249–256.
98.
RidgePG, EbbertMTW, KauweJSK (2013) Genetics of Alzheimer’s disease. BioMed Res Int2013, 254954.
99.
HollerCJ, DavisPR, BeckettTL, PlattTL, WebbRL, HeadE, MurphyMP (2014) Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer’s disease brain and correlates with neurofibrillary tangle pathology. J Alzheimers Dis42, 1221–1227.
100.
MorenoDJ, RuizS, RíosÁ, LoperaF, OstosH, ViaM, BedoyaG (2017) Association of GWAS top genes with late-onset Alzheimer’s disease in Colombian population. Am J Alzheimers Dis Other Demen32, 27–35.
101.
MasriI, SalamiA, El ShamiehS, Bissar-TadmouriN (2020) rs3851179G>A in PICALM is protective against Alzheimer’s disease in five different countries surrounding the Mediterranean. Curr Aging Sci13, 162–168.
102.
LeeE-G, ChenS, LeongL, TullochJ, YuC-E (2021) TOMM40 RNA transcription in Alzheimer’s disease brain and its implication in mitochondrial dysfunction. Genes12, 871.
103.
NishimuraA, NonomuraH, TanakaS, YoshidaM, MaruyamaY, AritomiY, SaundersAM, BurnsDK, LutzMW, RunyanG, LaiE, BudurK, RosesAD (2017) Characterization of and allele frequencies in the Japanese population. Alzheimers Dement (N Y)3, 524–530.
104.
LiuC-C, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
105.
KobayashiS, TatenoM, ParkTW, UtsumiK, SohmaH, ItoYM, KokaiY, SaitoT (2011) Apolipoprotein E4 frequencies in a Japanese population with Alzheimer’s disease and dementia with Lewy bodies. PLoS One6, e18569.
106.
SafiehM, KorczynAD, MichaelsonDM (2019) ApoE4: An emerging therapeutic target for Alzheimer’s disease. BMC Med17, 64.
107.
SolomonA, TurunenH, NganduT, PeltonenM, LevälahtiE, HelisalmiS, AntikainenR, BäckmanL, HänninenT, JulaA (2018) Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: A subgroup analysis of a randomized clinical trial. JAMA Neurol75, 462–470.
108.
De Frutos-LucasJ, CuestaP, Ramírez-TorañoF, NebredaA, Cuadrado-SotoE, Peral-SuárezÁ, Lopez-SanzD, BruñaR, Marcos-de PedroS, Delgado-LosadaML, López-SobalerAM, Concepción Rodríguez-RojoI, BarabashA, Serrano RodriguezJM, LawsSM, DoladoAM, López-HigesR, BrownBM, MaestúF (2020) Age and APOE genotype affect the relationship between objectively measured physical activity and power in the alpha band, a marker of brain disease. Alzheimers Res Ther12, 113.
109.
CreanS, WardA, MercaldiCJ, CollinsJM, CookMN, BakerNL, ArrighiHM (2011) Apolipoprotein E ɛ4 prevalence in Alzheimer’s disease patients varies across global populations: A systematic literature review and meta-analysis. Dement Geriatr Cogn Disord31, 20–30.
110.
El ShamiehS, CostanianC, KassirR, Visvkis-SiestS, Bissar-TadmouriN (2019) APOE genotypes in Lebanon: Distribution and association with hypercholesterolemia and Alzheimer’s disease. Pers Med16, 15–23.
111.
NakamuraT, WatanabeA, FujinoT, HosonoT, MichikawaM (2009) Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Mol Neurodegener4, 35.
112.
TaiLM, MehraS, SheteV, EstusS, RebeckGW, BuG, LaDuMJ (2014) Soluble apoE/Aβ complex: Mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener9, 2.
113.
LimAS, YuL, KowgierM, SchneiderJA, BuchmanAS, BennettDA (2013) Modification of the relationship of the apolipoprotein E ɛ4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol70, 1544–1551.
114.
DingX, ZhangS, JiangL, WangL, LiT, LeiP (2021) Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: A systematic review and meta-analysis. Transl Neurodegener10, 10.
115.
KarimR, KocM, RettbergJR, HodisHN, HendersonVW, St. JohnJA, AllayeeH, BrintonRD, MackWJ (2019) Apolipoprotein E4 genotype in combination with poor metabolic profile is associated with reduced cognitive performance in healthy postmenopausal women: Implications for late onset Alzheimer’s disease. Menopause26, 7–15.
116.
HusainMA, LaurentB, PlourdeM (2021) APOE and Alzheimer’s disease: From lipid transport to physiopathology and therapeutics. Front Neurosci15, 630502.
117.
Le BerI, De SeptenvilleA, GuerreiroR, BrasJ, CamuzatA, CaroppoP, LattanteS, CouarchP, KabashiE, Bouya-AhmedK, DuboisB, BriceA (2014) Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiol Aging35, 2419.e23-2419.e25.
118.
KleinbergerG, YamanishiY, Suárez-CalvetM, CzirrE, LohmannE, CuyversE, StruyfsH, PettkusN, Wenninger-WeinzierlA, MazaheriF, TahirovicS, LleóA, AlcoleaD, ForteaJ, WillemM, LammichS, MolinuevoJL, Sánchez-ValleR, AntonellA, RamirezA, HenekaMT, SleegersK, van der ZeeJ, MartinJJ, EngelborghsS, Demirtas-TatlidedeA, ZetterbergH, Van BroeckhovenC, GurvitH, Wyss-CorayT, HardyJ, ColonnaM, HaassC (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med6, 243ra86.
119.
KawaboriM, KacimiR, KauppinenT, CalosingC, KimJY, HsiehCL, NakamuraMC, YenariMA (2015) Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J Neurosci35, 3384–3396.
120.
YangJ, FuZ, ZhangX, XiongM, MengL, ZhangZ (2020) TREM2 ectodomain and its soluble form in Alzheimer’s disease. J Neuroinflammation17, 204.
AtagiY, LiuC-C, PainterMM, ChenX-F, VerbeeckC, ZhengH, LiX, RademakersR, KangSS, XuH, YounkinS, DasP, FryerJD, BuG (2015) Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem290, 26043–26050.
126.
JendresenC, ÅrskogV, DawsMR, NilssonLNG (2017) The Alzheimer’s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. J Neuroinflammation14, 59.
127.
CadyJ, KovalED, BenitezBA, ZaidmanC, Jockel-BalsarottiJ, AllredP, BalohRH, RavitsJ, SimpsonE, AppelSH (2014) TREM2 variant p. R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol71, 449–453.
128.
WangY, CellaM, MallinsonK, UlrichJD, YoungKL, RobinetteML, GilfillanS, KrishnanGM, SudhakarS, ZinselmeyerBH, HoltzmanDM, CirritoJR, ColonnaM (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell160, 1061–1071.
129.
JonssonT, StefanssonH, SteinbergS, JonsdottirI, JonssonPV, SnaedalJ, BjornssonS, HuttenlocherJ, LeveyAI, LahJJ, RujescuD, HampelH, GieglingI, AndreassenOA, EngedalK, UlsteinI, DjurovicS, Ibrahim-VerbaasC, HofmanA, IkramMA, Van DuijnCM, ThorsteinsdottirU, KongA, StefanssonK (2013) Variant of associated with the risk of Alzheimer’s disease. N Engl J Med368, 107–116.
JinSC, CarrasquilloMM, BenitezBA, SkorupaT, CarrellD, PatelD, LincolnS, KrishnanS, KachadoorianM, ReitzC, MayeuxR, WingoTS, LahJJ, LeveyAI, MurrellJ, HendrieH, ForoudT, Graff-RadfordNR, GoateAM, CruchagaC, Ertekin-TanerN (2015) TREM2 is associated with increased risk for Alzheimer’s disease in African Americans. Mol Neurodegener10, 19.
132.
ShiY, HoltzmanDM (2018) Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol18, 759–772.
133.
Carnero-PardoC, Rego-GarcíaI, Mené LlorenteM, Alonso RódenasM, Vílchez CarrilloR (2022) Diagnostic performance of brief cognitive tests in cognitive impairment screening. Neurologia (Engl Ed)37, 441–449.
134.
OssenkoppeleR, Pichet BinetteA, GrootC, SmithR, StrandbergO, PalmqvistS, StomrudE, TidemanP, OhlssonT, JögiJ, JohnsonK, SperlingR, DoreV, MastersCL, RoweC, VisserD, Van BerckelBNM, Van Der FlierWM, BakerS, JagustWJ, WisteHJ, PetersenRC, JackCR, HanssonO (2022) Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med28, 2381–2387.
135.
LeuzyA, SmithR, CullenNC, StrandbergO, VogelJW, BinetteAP, BorroniE, JanelidzeS, OhlssonT, JögiJ (2022) Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol79, 149–158.
136.
JiangY, ZhouX, IpFC, ChanP, ChenY, LaiNC, CheungK, LoRM, TongEP, WongBW (2022) Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer’s disease screening and staging. Alzheimers Dement18, 88–102.
137.
SmirnovDS, AshtonNJ, BlennowK, ZetterbergH, SimrénJ, Lantero-RodriguezJ, KarikariTK, HinikerA, RissmanRA, SalmonDP, GalaskoD (2022) Plasma biomarkers for Alzheimer’s disease in relation to neuropathology and cognitive change. Acta Neuropathol (Berl)143, 487–503.
138.
BanackSA, StarkAC, CoxPA (2022) A possible blood plasma biomarker for early-stage Alzheimer’s disease. PLoS One17, e0267407.
139.
MavroudisI, ChowdhuryR, PetridisF, KarantaliE, ChatzikonstantinouS, BalmusIM, LucaIS, CiobicaA, KazisD (2021) YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer’s disease. Medicina (Mex)58, 60.
140.
Lustig-BarzelayY (2022) Machine learning for comprehensive prediction of high risk for Alzheimer’s disease based on chromatic pupilloperimetry. Sci Rep12, 9945.
141.
KavithaC, ManiV, SrividhyaSR, KhalafOI, Tavera RomeroCA (2022) Early-stage Alzheimer’s disease prediction using machine learning models. Front Public Health10, 853294.
PrinceM, AlbaneseE, GuerchetM, PrinaM (2014) World Alzheimer Report 2014. Dementia and Risk Reduction: An analysis of protective and modifiable risk factors. Alzheimer’s Disease International, London, UK.
144.
ButlerM, NelsonVA, DavilaH, RatnerE, FinkHA, HemmyLS, McCartenJR, BarclayTR, BrasureM, KaneRL (2018) Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: A systematic review. Ann Intern Med168, 52–62.
145.
Arevalo-RodriguezI, SmailagicN, Roqué FigulsIM, CiapponiA, Sanchez-PerezE, GiannakouA, PedrazaOL, Bonfill CospX, CullumS (2015) Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev2015, CD010783.
146.
EscobarJI, BurnamA, KarnoM, ForsytheA, LandsverkJ, GoldingJM (1986) Use of the Mini-Mental State Examination (MMSE) in a community population of mixed ethnicity: Cultural and linguistic artifacts. J Nerv Ment Dis174, 607–614.
TerwilligerJD (2022) Gene mapping and human disease. In Genetics of Substance Use: Research and Clinical Aspects. Springer, pp. 147-175.
149.
BallariniT, Melo Van LentD, BrunnerJ, SchröderA, WolfsgruberS, AltensteinS, BrosseronF, BuergerK, DechentP, DobischL, DüzelE, Ertl-WagnerB, FliessbachK, FreieslebenSD, FrommannI, GlanzW, HauserD, HaynesJD, HenekaMT, JanowitzD, KilimannI, LaskeC, MaierF, MetzgerCD, MunkMH, PerneczkyR, PetersO, PrillerJ, RamirezA, RauchmannB-S, RoyN, SchefflerK, SchneiderA, SpottkeA, SpruthEJ, TeipelSJ, VukovichR, WiltfangJ, JessenF, WagnerM, on behalf of the DELCODE Study Group (2021) Mediterranean diet, Alzheimer disease biomarkers, and brain atrophy in old age. Neurology96, e2920–e2932.
150.
SolchRJ, AigbogunJO, VoyiadjisAG, TalkingtonGM, DarensbourgRM, O’ConnellS, PickettKM, PerezSR, MaraganoreDM (2022) Mediterranean diet adherence, gut microbiota, and Alzheimer’s or Parkinson’s disease risk: A systematic review. J Neurol Sci434, 120166.
151.
JeongW, LeeH, ChoS, SeoJ (2019) ApoE4-induced cholesterol dysregulation and its brain cell type-specific implications in the pathogenesis of Alzheimer’s disease. Mol Cells42, 739–746.
152.
GuglielmottoM, GilibertoL, TamagnoE, TabatonM (2010) Oxidative stress mediates the pathogenic effect of different Alzheimer’s disease risk factors. Front Aging Neurosci2, 3.
153.
ClausenBH, LambertsenKL, BabcockAA, HolmTH, Dagnaes-HansenF, FinsenB (2008) Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation5, 46.
154.
NguyenAT, WangK, HuG, WangX, MiaoZ, AzevedoJA, SuhE, Van DeerlinVM, ChoiD, RoederK, LiM, LeeEB (2020) APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer’s disease. Acta Neuropathol (Berl)140, 477–493.
155.
SteenlandK, GoldsteinFC, LeveyA, WhartonW (2016) A meta-analysis of Alzheimer’s disease incidence and prevalence comparing African-Americans and Caucasians. J Alzheimers Dis50, 71–76.
156.
WillisF, Graff-RadfordN, PintoM, LawsonL, EpsteinD, ParfittF, HuftonM, O’BrienPC (2003) Apolipoprotein E4 allele frequency in young Africans of Ugandan descent versus African Americans. J Natl Med Assoc95, 71–76.
157.
MalkkiH (2015) The involvement of TREM2 R47H variant in Alzheimer disease confirmed, but mechanisms remain elusive. Nat Rev Neurol11, 307–307.
